在阿尔茨海默氏病中,阿波利波蛋白E,胆固醇和粉样蛋白之间的相互作用引起的治疗挑战
1Departamento de Medicina, Facultad de Ciencias de la Salud, Universidad de Oviedo, ES-33006 Oviedo, Spain.
International journal of molecular sciences
|November 27, 2024
概括
阿波利波蛋白E4 (ApoE4) 异型是阿尔茨海默病 (AD) 的主要遗传风险,影响胆固醇和β-粉样蛋白代谢. 本综述探讨了ApoE4载体的治疗策略和挑战.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 脂蛋白E (ApoE) E4异型是晚发性阿尔茨海默病 (AD) 的重要遗传风险因素.
- ApoE影响胆固醇运输和粉样蛋白-β (Aβ) 代谢,这是AD病变发生的关键途径.
- ApoE4与胆固醇稳定性受损,Aβ聚合加速和陶酸化增加有关.
研究的目的:
- 检查阿波E异型,胆固醇代谢和AD中的粉样蛋白病理学之间的复杂关系.
- 审查在ApoE4载体中对AD治疗的治疗挑战和决策考虑.
主要方法:
- 文献综述和对ApoE,胆固醇和β-粉样蛋白的现有研究进行分析.
- 检查药理干预措施,包括降脂剂,免疫疗法和抗凝剂.
- 对具有ApoE4基因型的个体的临床影响和治疗策略的讨论.
主要成果:
- 突出了ApoE4在通过中断的脂质代谢和增强的Aβ聚合来加剧AD病理方面的作用.
- 治疗干预措施,如他类药物,PCSK9抑制剂和抗粉样蛋白疗法为ApoE4载体带来了独特的挑战和好处.
- 在选择治疗时需要复杂的决策,在这个患者群体中平衡疗效与潜在风险.
结论:
- 了解ApoE异型体,胆固醇和粉样蛋白的相互作用对于开发有效的AD疗法至关重要.
- 需要有针对性的治疗策略来解决ApoE4异型的特定病理贡献.
- 进一步的研究对于优化治疗决策和改善携带ApoE4风险因子的阿尔茨海默病患者的治疗结果至关重要.
相关概念视频
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
01:26Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
01:30Dementia
96
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
96
03:03Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
98
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
98
01:23Factors Affecting Protein-Drug Binding: Drug Interactions
105
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
105